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Post-remission strategies after dasatinib-corticosteroid induction in adult Philadelphia
chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) are not well studied. We
evaluated dasatinib and dexamethasone induction then protocol-defined post-remission
therapies, including hematopoietic cell transplantation (HCT). Adults (N5 65) with Ph-positive
ALL received dasatinib-dexamethasone induction, methotrexate-based central nervous
system (CNS) prophylaxis, reduced-intensity conditioning (RIC) allogeneic HCT, autologous
HCT, or chemotherapy alone, and dasatinib-based maintenance. Key end points were disease-
free survival (DFS) and overall survival (OS). Themedian agewas 60 years (range, 22-87 years).
The complete remission rate was 98.5%. With a median follow-up of 59 months, 5-year DFS
and OS were 37% (median, 30 months) and 48% (median, 56 months), respectively. For
patients receiving RIC allogeneic HCT, autologous HCT, or chemotherapy, 5-year DFS were
49%, 29%, and 34%, and 5-year OSwere 62%, 57%, and 46%, respectively. Completemolecular
response rate after CNS prophylaxis was 40%. Relative to the p190 isoform, p210 had shorter
DFS (median 10 vs 34 months, P 5 .002) and OS (median 16 months vs not reached, P 5 .05).
Relapse occurred in 25% of allogeneic HCT, 57% of autologous HCT, and 36% of chemotherapy
patients. T315Imutationwas detected in 6 of 8marrow relapses. Dasatinib CNS concentrations
were low. Dasatinib-dexamethasone followed by RIC allogeneic HCT, autologous HCT, or
chemotherapy was feasible and efficacious, especially with RIC allogeneic HCT. Future studies
should address the major causes of failure: T315I mutation, the p210 BCR-ABL1 isoform, and
CNS relapse. This study was registered at www.clinicaltrials.gov as #NCT01256398.
Introduction
In adult patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL), adding
the first-generation BCR-ABL1–targeted tyrosine kinase inhibitor (TKI) imatinib to chemotherapy yielded
improved response and survival compared with chemotherapy alone due to more imatinib-treated patients
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proceeding to hematopoietic cell transplantation (HCT).1-5 Second-
generation TKIs appear to have further improved survival,6-9 but mye-
loablative (MA) allogeneic HCT still may be the optimal postremission
therapy.10 MA autologous HCT and reduced-intensity (RIC) alloge-
neic HCT have shown efficacy and are appealing for older or less fit
patients. Autologous HCT has shown similar outcomes to allogeneic
HCT and superior outcomes to chemotherapy, with 4- to 5-year DFS
of 46% to 80%.2,5,11,12 Similarly, RIC allogeneic HCT for ALL yields
2- to 3-year survival of 39% to 48%, non-relapse mortality (NRM) of
21% to 25%, and relapse rates of 40% to 49%.13-16 The efficacy
of allogeneic HCT is likely due in part to graft-versus-leukemia
effect.17-19
Prior studies support reduced-intensity (RI), TKI-based induction for
Ph-positive ALL, yielding complete response (CR) rates of 95% to
100% and nearly no induction deaths.5,20-23 GRAAPH-2005, com-
paring RI induction with imatinib, dexamethasone, and vincristine to
imatinib with HyperCVAD (hyper-fractionated cyclophosphamide, vin-
cristine, adriamycin, and dexamethasone alternating with high-dose
methotrexate and high-dose cytarabine), showed a superior CR rate
due to less induction death with the RI approach.5 In LALA1205,
dasatinib and prednisone induction followed by investigator-chosen
postremission therapy yielded a CR rate of 100%, but relapse was
common without subsequent allogeneic HCT or intensive
chemotherapy.22
Relapse after second-generation TKI-based therapy is primarily due to
clones with the BCR-ABL1 T315I resistance mutation, as seen in
71% to 75% of relapses after dasatinib.22,24 Chemotherapy or
HCTmay eliminate these clones, and this likely accounts for the supe-
rior outcomes seen with intensive postremission strategies.9,22,23
Recent reports suggest that ponatinib, which inhibits BCR-ABL1
T315I, together with corticosteroids or chemotherapy but without
consolidative HCT, appears to be highly effective.25,26
Here, we present results of Cancer and Leukemia Group B (CALGB)
10701, a prospective study of Ph-positive ALL treatment using induc-
tion with dasatinib and dexamethasone followed by high-dose
methotrexate–based central nervous system (CNS) prophylaxis and
allocation to RIC allogeneic HCT, MA autologous HCT, or chemother-
apy alone based on donor availability and patient age.
Methods
Patients
Patients were enrolled from December 2010 to November 2014 at
17 US centers. Eligible were adults ages $18 years with
Ph-positive ALL defined by the t(9;22)(q34;q11) or 3-way variant by
metaphase cytogenetics, BCR-ABL1 by fluorescence in situ hybridi-
zation, and/or BCR-ABL1 by reverse transcription polymerase chain
reaction (RT-PCR). Prior therapy was excluded except for #1 week
of corticosteroids and/or hydroxyurea. Eligible patients had adequate
cardiac function.
Design
The study was a phase 2, 3-arm, nonrandomized trial
(NCT01256398) with primary objectives to estimate DFS and OS
of the whole population. The goal was to establish relevant baseline
survival and toxicity data to inform future study design. Sample size
was based on safety/feasibility. Considering a treatment-related mor-
tality rate .0.4 as unacceptable and ,0.2 as acceptable, 60
evaluable patients would yield 92% power with a 2-sided a of .05.
All participating sites acquired institutional review board approval prior
to enrolling patients. All patients provided written informed consent.
The study was conducted in accordance with the Declaration of
Helsinki.
Treatments
Induction (course I) used dexamethasone 10 mg/m2 per day orally or
IV days 1 to 7 and dasatinib 140 mg orally daily. A bone marrow
biopsy was performed on day 15. If the day 15 marrow had #20%
lymphoblasts, course II continued dasatinib 140 mg oral daily with
another 7 days of dexamethasone as in course I. If the day 15 marrow
had .20% lymphoblasts, patients also received vincristine and dau-
norubicin. Patients not in CR or CRi (CRwith incomplete count recov-
ery) on bone marrow biopsy after course II received a second
induction course (course III) with dasatinib, cyclophosphamide, vin-
cristine, daunorubicin, and dexamethasone. Patients in CR/CRi after
course II/III proceeded to course IV. CNS prophylaxis (course IV)
used IV vincristine and IV methotrexate 1000 mg/m2 (n 5 5) or
500 mg/m2 (after 21 May 2012; n 5 50), oral methotrexate, and 3
doses of intrathecal methotrexate. Course V consisted of HCT or che-
motherapy alone. Patients 18 to 70 years underwent RIC allogeneic
HCT if they had a 6/6 or 5/6 HLA-matched sibling or 8/8 HLA-
matched unrelated donor. Otherwise, they underwent autologous
HCT. Allogeneic HCT conditioning used fludarabine 30 mg/m2 per
day IV on days 27 through 23, alemtuzumab 20 mg/day IV on
days 27 through 23, and melphalan 140 mg/m2 IV once on day
22. Graft-versus-host disease (GVHD) prophylaxis with tacrolimus
began on day22. Patients undergoing autologous HCT received eto-
poside 10 mg/kg per day (age.65 years, 5 mg/kg per day) continu-
ous IV for 4 days and cytarabine 2 g/m2 (age .65 years, 1 g/m2) IV
every 12 hours for 8 doses followed by filgrastim for mobilization.
Autologous HCT conditioning was melphalan 100 mg/m2 per day
IV on days 22 and 21. Patients .70 years or unable to undergo
HCT received etoposide/cytarabine alone. Dasatinib maintenance
(course VI, HCT cohorts) or dasatinib with mercaptopurine, vincristine,
methotrexate, and dexamethasone (POMD; chemotherapy cohort)
began on day 30 of course V and continued for$12 months and until
2 consecutive negative BCR-ABL1 RT-PCR assay results 3 months
apart or relapse (Figure 1; supplemental Figure 1).
End point assessment
Hematologic, cytogenetic, and molecular responses were assessed
locally. A CR required an absolute neutrophil count (ANC) .1 3
103/mL, platelets .100 3 103/mL, no circulating blasts, adequate
marrow cellularity with trilineage hematopoiesis and,5% blasts, res-
olution of extramedullary disease, and transfusion independence. CRi
was identical to CR except for ANC ,1000/mL or platelets
,100000/mL. Complete cytogenetic remission (CCyR) required no
clonally abnormal cells in$20marrow metaphases. Complete molec-
ular remission (CMR) required no detectable BCR-ABL1 transcripts
in a quantitative RT-PCR assay with a sensitivity of$1:10000. Major
molecular remission (MMR) required a ratio of BCR-ABL1 transcripts
to ABL1 transcripts of#0.1%. Relapse was defined as the reappear-
ance of lymphoblasts in the blood, marrow (.5%), cerebrospinal fluid
(CSF), or other extramedullary site after a CR/CRi. BCR-ABL1 iso-
form and ABL1 kinase domain (KD) mutation determinations were
performed locally and collected retrospectively. DFS was measured
from CR/CRi to relapse or death, with patients censored at last
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time known to be alive and disease-free. OS was from therapy start to
death, with patients censored at the last time known to be alive.
Dasatinib pharmacokinetics
Blood and CSF were collected in EDTA on day 15 of course I,
2 to 3 hours after oral dasatinib. Plasma was prepared by centri-
fugation of blood at 2000g for 5 minutes at 4C and then frozen.
CSF was processed similarly. Plasma dasatinib concentrations
were quantitated by liquid chromatography tandem mass spectrom-
etry.27 For quantitation of low dasatinib CSF concentrations, the
assay was modified. Specifically, the concentration range of 0.1
to 100 ng/mL was made in 50/50 PBS/plasma with a lower con-
centration of internal standard (100 ng/mL). CSF was diluted 1:1
in control plasma. Detection used an ABI SCIEX (San Jose, CA)
4000Q hybrid linear ion trap tandem mass spectrometer with elec-
trospray ionization operated in the positive and multiple reaction
monitoring mode. The high-performance liquid chromatography sys-
tem and mass spectrometer were controlled by and data
collected with Analyst software (version 1.4.2). The analyte-to-inter-
nal standard ratio was calculated for each standard by dividing
the area of analyte peak by the area of the respective internal stan-
dard peak for the sample. Standard curves of analytes were con-
structed by plotting the analyte-to-internal standard ratio vs the
known concentration of analyte in each sample. Standard curves
were fit by linear regression with weighting by 1/y2, followed by
back calculation of unknown concentrations. Under these
conditions, the assay was linear, accurate (95.3% to 106.0%),
and precise (2.51% to 6.75%) in the range of 0.1 to 100 ng/
mL. a1-Acid glycoprotein (orosomucoid; AGP) was quantitated
Course I (Induction)
Bone marrow biopsy Day 15
Dasatinib, Dexamethasone
Dasatinib 140 mg oral daily; Dexamethasone 10 mg/m2/d oral/IV day 1-7
>20% lymphoblasts
Course IIA
Dasatinib, Dexamethasone, Vincristine, Daunorubicin
Course IIB
CR/CRi No CR/CRi
Dasatinib, Cyclophosphamide, Vincristine, Daunorubicin, Dexamethasone
Course III
Bone marrow biopsy Day 29
CR/CRi
Vincristine, Methotrexate IV, oral, intrathecal, Dasatinib
Course IV (CNS Prophylaxis)
Bone marrow biopsy Day 43 (Molecular response assessment)
Age 18-70, HLA-matched donor
Course V
Age 18-70, no HLA-matched donor Age >70 or unfit
Allogeneic HCT Autologous HCT Alternative Chemotherapy
Conditioning Mobilization Etoposide, Cytarabine
Etoposide, Cytarabine
G-CSF 10 mcg/kg/day starting day 14 until
collection of ≥5 x 10^6 CD34+ cells/kg
Dasatinib after completion of collection
Day 0 = hematopoietic cell infusion
Post HCT GVHD Prophylaxis
Autologous HCT Conditioning
Melphalan
Day 0 = hematopoietic cell infusion
Tacrolimus CIV/PO, trough 10-20 ng/mL
Course VI (Maintenance)
Allogeneic HCT Autologous HCT Alternative Chemotherapy
Dasatinib 50-100 mg PO daily starting 
day +30
Dasatinib 100 mg PO daily starting day +30 Dasatinib 100 mg PO daily starting day +30
Continue for 12 months and 2 negative 
BCR-ABL1 QPCR 3 months apart
Continue for 12 months and until 2 negative Mercaptopurine, Vincristine, Methotrexate,
BCR-ABL1 QPCR 3 months apart Dexamethasone (POMD)
Continue for 12 months and until 2 negative
BCR-ABL1 QPCR 3 months apart
Bone marrow biopsy Day 22
≤20% lymphoblasts
Fludarabine, Alemtuzumab, Melphalan
Figure 1. Treatment schema. CIV, continuous IV; G-CSF, granulocyte colony-stimulating factor; PO, by mouth; QPCR, quantitative RT-PCR.
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by ELISA kits (R&D Systems, catalog #DAGP00) and AssayPro
(catalog #EG5101-1), respectively. All samples were tested in
duplicate.
Statistical analysis
The analysis population was eligible patients receiving $1 dose of
dasatinib. The primary end points were DFS and OS. Secondary
end points were DFS and OS of the course V cohorts, the efficacy
of dasatinib maintenance, the ability to collect peripheral blood hema-
topoietic stem cell collection after dasatinib, the safety and efficacy of
HCT after dasatinib, the safety and efficacy of dasatinib maintenance,
and the correlation between plasma and CSF levels of dasatinib. For
secondary end points, proportions were estimated based on the com-
bined and individual course V cohorts. Time-to-event distributions
were estimated using the Kaplan-Meier methods and compared using
log-rank tests.28 Hazard ratios (HRs) and 95% confidence intervals
(CIs) were estimated using the Cox proportional hazards model.29
Subgroup analyses were further conducted by age, BCR-ABL1 tran-
script, molecular response at the end of course IV, and dasatinib con-
centrations in plasma and CSF. A competing risk analysis, with death
in remission as a competing risk, was used to compute the cumulative
incidence for relapse among patients achieving a CR/CRi. End points,
whenever scientifically plausible, for each cohort were compared in an
exploratory fashion. All analyses were conducted with 2-sided tests
and a significance level of .05 on the study database frozen on 17
October 2019. Data collection and statistical analyses were con-
ducted by the Alliance Statistics and Data Center. Data quality was
ensured by review of data by the Alliance Statistics and Data Center
and by the study chairperson following Alliance policies.
Results
Patient characteristics and disposition
Median age was 60 years (range, 22-87 years). BCR-ABL1 isoform
data were available for 50 patients (p190 in 76% and p210 in
24%) (Table 1). Of 65 patients starting course I, 60 achieved
,20% marrow lymphoblasts on day 15, 1 had .20% lymphoblasts,
3 did not tolerate course I, and 1 was removed. Fifty-five
patients entered course IV. Thirty-eight patients entered course V,
with 20 allocated to allogeneic HCT, 7 to autologous HCT, and 11
to chemotherapy. Eleven patients underwent off-study allogeneic
HCT in CR1, 2 after course IIA, 6 after course IV, 1 after course V che-
motherapy, 1 during course VI chemotherapy, and 1 after autologous
HCT due to engraftment failure. Two patients relapsing after
autologous HCT underwent allogeneic HCT. Five patients
skipped course V and then continued to course VI chemotherapy
maintenance (Figure 2).
Response
The overall CR rate (CR1 CRi) was 98.5%. Of 64 patients achieving
CR/CRi, 36 patients (55%) achieved CR/CRi after course I, 27
(42%) after course IIA, and 1 (2%) after course III. Of 43 patients
with molecular testing reported, 17 (40%) had CMR and 12 (28%)
had MMR by the end of course IV. The CCyR rate was 79%. Of
8 patients with the p210 isoform, 1 achieved CMR and 1 MMR by
the end of course IV (Table 2).
DFS and OS
With a median follow-up of 59 months (range, 38-90 months), the
5-year DFS was 37% (95% CI, 25% to 49%), and 5-year OS was
48% (95% CI, 35% to 61%, Figure 3). In landmark analyses starting
from course V, DFS at 5 years was 49% for allogeneic HCT, 29% for
autologous HCT, and 34% for chemotherapy alone, whereas OS at 5
years was 62%, 57%, and 46%, respectively. Median DFS for alloge-
neic HCT was 42 months vs 15 months for autologous HCT and 28
months for chemotherapy alone. Three of 7 autologous HCT
patients underwent subsequent allogeneic HCT, 2 for relapse and 1
Table 1. Patient and disease characteristics (N 5 65)
Patient and disease characteristics n (%)
Age (y)







American Indian or Alaska native 1 (1.5)
Not reported/unknown 3 (4.6)
Ethnicity
Not Hispanic or Latino 50 (76.9)
Hispanic or Latino 10 (15.4)
Unspecified 5 (7.7)





Median (range) 23 (0.3-434)
BCR-ABL1 transcript (n 5 50)
p190 38 (76)
p210 12 (24)





Monosomy 7 6others 7 (20)
Therapy for prior malignancy
None/not reported 56 (86.2)
Chemotherapy 2 (3.1)
Radiation therapy 5 (7.7)
Chemotherapy and radiation therapy 1 (1.5)
Unknown treatment 1 (1.5)
Data are presented as n (%) of patients, unless otherwise indicated.
ECOG, Eastern Cooperative Oncology Group; WBC, white blood cells.
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for engraftment failure. Compared with the p190 isoform, the p210
isoform was associated with worse DFS (5-year DFS, 8% vs
41%, P 5 .002) and worse OS (5-year OS, 17% vs 53%, P 5
.05, Figure 3). Age (#60 vs .60 years), CMR at end course IV
(yes vs no), and receiving an allogeneic HCT (any vs none) did
not impact DFS or OS. See supplemental Figure 2 for a swim plot
of all patients.
Dasatinib maintenance
Of 43 patients continuing on protocol therapy after course IV, including
5 patients who skipped course V, 36 (84%) proceeded to dasatinib
maintenance on protocol (Figure 2). Two patients relapsed during
maintenance, 1 with the T315I mutation and 1 with isolated CNS
relapse. Maintenance was completed by 25 patients, with 10 (40%)
Course IIB, N=1
Course IIA, N=60
Course V, Chemo, N=11
















Alive in CR1, N=2
Relapse, N=1
relapse, N=1
Alive in CR1, N=9
Completed
Relapse, N=1
Alive after relapse, N=3










Alive in CR1, N=2
Relapse, N=3
Off study AlloHCT in CR1, N=1





Off study AlloHCT, N=6
Skipped VI, N=1
Off study AlloHCT in
CR1, N=1
Skip Course V, N=5
Engraftment failure, N=1
Figure 2. Patient disposition. MI, myocardial infarction.
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relapsing after completion. Of these, 2 were isolated CNS relapses,
and of 2 marrow relapses tested, both had the T315I mutation.
Relapse and BCR-ABL1 KD mutation
Overall,25patients relapsedwith5CNSrelapses (3 isolated) (Table2).
Eighteen relapses (72%) occurred off treatment. No relapses occurred
prior to course IV. Relapse occurred in 25%of allogeneicHCT, 57%of
autologous HCT, and 36% of chemotherapy patients. Of 36 patients
entering maintenance, 9 died in remission, 2 relapsed onmaintenance,
and 10 relapsed after completion of maintenance. The cumulative inci-
dence of relapse was not significantly different among the 3 course V
cohorts (compared with chemotherapy, allogeneic HCT: HR, 0.62;
95% CI 0.18-2.12; autologous HCT: HR, 2.45; 95% CI 0.54-11.02).
Two patients relapsing after autologous HCT underwent allogeneic
HCT and are alive in remission. For 43 patients with end of course IV
molecular response data, relapse occurred in 5 out of 17 (29%) with
CMR, 2 out of 12 (17%) with MMR, and 8 out of 14 (57%) with less
than anMMR.Of 12 patientswith the p210 isoform, 9 (75%) relapsed,
2 (17%) died in remission, and 1 (8%) survives in CR. Of 37 patients
with the p190 isoform in CR, 11 (29%) relapsed, 11 (29%) died in
remission, and 15 (41%) survive in CR. Of 8 marrow relapses tested,
6 had the T315I mutation (75%) and 2 had no ABL1 KD mutation.
Whereas both patients relapsing without a T315I were off treatment
at relapse, 4 of 6 with a T315I mutation relapsed on treatment.
Tolerability
Five patients discontinued during dasatinib/dexamethasone induction
due to adverse events, including hyperglycemia, pulmonary infiltrates,
fluid overload, sepsis, and prolonged QTc. No on-treatment deaths
occurred until course V. Fifteen patients died in CR, 9 from complica-
tions after allogeneic HCT and 6 while on dasatinib or dasatinib/
POMD (3 myocardial infarction/cardiac arrest, 1 stroke, 1 neutropenic
sepsis, and 1 unknown). RIC allogeneic HCT was judged to be feasi-
ble, with 5 deaths (25%) from transplant-related complications (3
GVHD, 1 sepsis, and 1 posttransplant lymphoproliferative disorder).
All 7 autologous HCT patients had robust hematopoietic stem cell
mobilization (median, 92.5 3 106 CD341/kg; range, 30.6-886). Sur-
prisingly, 2 of 7 autologous HCT patients failed to fully engraft (1 no
engraftment and 1 prolonged thrombocytopenia) followed by salvage
allogeneic HCT in one and relapse in the other. Both had the p210
isoform. Dasatinib maintenance was tolerable, with 72%, 80%, and
80% receiving at least 50% of plannedmaintenance doses in the allo-
geneic HCT, autologous HCT, and chemotherapy arms, respectively.
Dasatinib concentrations in plasma and CSF
The median plasma dasatinib concentration was 52.4 ng/mL (range,
,lower limit of quantitation [LLQ]-308) with a median AGP concen-
tration of 1170 mg/mL (range, 482-9920; n 5 40). The median
CSF dasatinib concentration was 0.348 ng/mL (range, ,LLQ-1.37)
with a median AGP concentration of 12.1 mg/mL (range, 2.99-46;
N5 39). Based on the samples with dasatinib concentrations above
the LLQ in plasma (n 5 35) and CSF (n 5 31), we could calculate
CSF/plasma ratios in 28 patient samples. Median CSF dasatinib con-
centrations were 0.66% of the plasma dasatinib concentration (range,
0.09% to 15.8%). DFS and OS were shorter with plasma dasatinib
concentrations less than the median (30.3 ng/mL, the median value
when imputing zero for,LLQ, n5 5), although not statistically signif-
icant (5-year DFS, 32% vs 42%, P 5 .28; 5-year OS, 37% vs 60%,
P5 .13, respectively; Figure 3).
Discussion
In adult Ph-positive ALL, adding cytotoxic chemotherapy to TKIs
with corticosteroids in induction does not improve hematologic
response but does increase early mortality.5 Supporting previous
studies,20-22,24,25 we observed a CR/CRi rate of 98.5% with
Table 2. Response and relapse (N 5 65)
Total n %
Overall CR (CR 1 CRi)* 64 98.5
CR 62 95.4
CR with incomplete count recovery 2 3.1
Refractory 1 1.5
Overall CR by course 64
I (n 5 65) 36† 55.4
IIA (n 5 60) 27 41.5
IIB (n 5 1) 0 0
III (n 5 2) 1 1.5
Molecular response end of course IV 43
CMR 17 39.5
MMR 12 27.9
Less than MMR 14 32.6
Cytogenetic response end of course IV 34
CCyR 27 79.4
Less than CCyR 7 20.6
Relapse during each course 25
I 0 0
IIA/IIB/III 0 0
IV: CNS prophylaxis 2 8
V 3 12
Allogeneic HCT (n 5 20) 1
Autologous HCT (n 5 7) 2
Chemotherapy (n 5 11) 0
VI: maintenance 2 8
Allogeneic HCT (n 5 18) 0
Autologous HCT (n 5 4) 1‡
Chemotherapy (n 5 9) 1§
Follow-up after completion of maintenance 10 40
Allogeneic HCT (n 5 13) 4‡(1),§(1)
Autologous HCT (n 5 3) 1
Chemotherapy (n 5 6) 3‡ (1),§(1)
Skipped course V (n 5 3) 2
Off-protocol therapy 8 32
Adverse events 4
Patient refusal/noncompliance 3‡ (1)
Off-protocol allogeneic HCT 1‡
The bold are the categories of outcomes that are broken down below each bold category/
outcome.
*Before course IV.
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dasatinib and dexamethasone induction, with no induction deaths.
Without adequate postremission therapy, however, most patients
relapse.22 Of 6 patients on our study not receiving intensive postre-
mission chemotherapy or HCT, only 1 remains alive in remission.
Until recently, intensive induction with cytotoxic chemotherapy plus a
TKI has been a standard approach for Ph-positive ALL, although these
regimens are associated with lower remission rates and higher early
mortality than low-intensity induction with TKIs and corticosteroids
B
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+ Censor























12 24 36 48 60














12 24 36 48 60
UNKNOWN 13 12 10 4
















p190 18/38 NE (31.8-NE)








p190/p210 Events/Total Median (95% CI) HR (95% CI)
D
UNKNOWN 13 9 9 4
















p190 22/37 33.8 (24.8-NE)




















12 24 36 48 60














12 24 36 48 60
65 56 46 36 25 15
33/65 55.9 (31.8-NE)
+ Censor











Median (95% CI)Events/Total 
E
<30.3 19 15 11 8 5




















0 12 24 36 48 60


























12 24 36 48 60
<30.3 19 13 9 6 4




















Events/Total Median (95% CI) HR (95% CI)Plasma Group
Figure 3. OS and DFS. OS (A) and DFS (B) for the entire cohort. OS (C) and DFS (D) by p190 vs p210 BCR-ABL1 isoform status. OS (E) and DFS (F) by plasma dasatinib levels.
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with or without vincristine.4-10,25,30,31 The Southwest Oncology
Group (SWOG) 0805 trial studied intensive treatment with Hyper-
CVAD and dasatinib in younger patients (age, 18-60 years) with newly
diagnosed Ph-positive ALL with patients allocated to myeloablative
allogeneic HCT if they had a donor.10 The CR/CRi rate was 88%,
with 2 early deaths, in contrast to a 98.5% CR/CRi and no early
deaths in our study supporting low-intensity induction as a safer and
more effective induction option for newly diagnosed Ph-positive
ALL. Patients on SWOG 0805 with a 10/10 HLA-matched donor
were allocated to myeloablative allogeneic HCT followed by dasatinib
maintenance. Compared with HyperCVAD plus dasatinib alone, trans-
planted patients had a superior relapse-free survival (3-year, 76% vs
51%, P 5 .038). Patients treated with RIC allogeneic HCT on this
study had a somewhat lower relapse-free survival/DFS (3-year,
60%), although differences in disease and patient characteristics,
including older age in this study, rather than the conditioning may
account for the differences. Myeloablative conditioning remains the
preferred approach for Ph-positive ALL in eligible patients, with RIC
or nonmyeloablative conditioning being options for older or less fit
patients. Randomized study is needed to better delineate optimal con-
ditioning for Ph-positive ALL in the era of second- and third- genera-
tion TKIs.
Optimal postremission therapy after second-generation TKIs is still
being determined, although nonrandomized studies support alloge-
neic HCT.10,22,23 Unlike our study, however, prior studies of
second-generation TKI plus corticosteroid induction have not speci-
fied postremission therapy.22 Myeloablative conditioning has tradition-
ally been preferred due to lower rates of relapse, but with high
NRM.15,16 Graft-versus-leukemia appears active in ALL, leading to a
decreased risk of relapse with mild-moderate acute GVHD and
chronic GVHD.17-19 Thus, RIC may be a viable option, especially for
older patients unlikely to tolerate myeloablative conditioning. Indeed,
we observed a low relapse incidence with RIC allogeneic HCT, con-
sistent with retrospective reports.13-16 Autologous HCT is also effica-
cious for Ph-positive ALL,2,5,11,12 but our study had too few patients
undergoing autologous HCT to draw conclusions. In addition, 3
patients received allogeneic HCT after autologous HCT further limit-
ing interpretation of a role for autologous HCT. A concerning finding
is that 2 of 7 patients undergoing autologous HCT had engraftment
failure, raising the possibility that dasatinib may negatively affect the
engraftment potential of the hematopoietic cell product.
The recently published, nonrandomized GIMEMA LAL2116 D-ALBA
study reported outcomes of dasatinib plus corticosteroid induction fol-
lowed by blinatumomab in adults with newly diagnosed Ph-positive
ALL. The CR rate was 98%, with a CMR rate of 60% after 2 cycles
blinatumomab. With a relatively short (18-month) median follow-up,
DFS and OS were 95% and 88%, respectively.30 Our study, with a
59-month median follow-up, also reports favorable short- and long-
term results with similar induction but more traditional postremission
therapy approaches appropriate for older and less fit patients. Taken
together, the results of our study and the D-ALBA study provide impor-
tant information for clinical decision making and a potential random-
ized study to identify the optimal postremission approach for
Ph-positive ALL, especially for older patients after dasatinib and corti-
costeroid induction.
The duration of dasatinib maintenance and optimal conditions for
stopping dasatinib maintenance are not known. In this study, molecu-
lar response guided stopping of dasatinib, with a minimum of 1 year of
maintenance. The relapse rate after stopping maintenance was 40%
but was highly associated with T315I mutations and isolated CNS
relapses, suggesting that more prolonged maintenance would have
been unlikely to prevent relapse. Targeting T315I with ponatinib and
improving CNS prophylaxis may improve outcomes with this regimen.
Two ongoing studies show very low relapse rates with ponatinib with
corticosteroids or HyperCVAD chemotherapy.25,26
Compared with the p190 isoform, the p210 isoform was associated
with significantly worse DFS and OS. Worse DFS with p210 was
also seen in CALGB 10001 (a similar trial using imatinib) and the
GIMEMA LAL 1509 study of dasatinib and corticosteroid induction
followed by chemotherapy or allogeneic HCT.31,32 One reason may
be that some p210 ALL patients represent CML in lymphoid blast cri-
sis. Biologic differences and co-occurring mutations including Ikaros
mutations were not assessed in this study and may contribute to
the inferior outcomes in the p210 population.
In this study, plasma dasatinib concentrations were comparable to
those expected (Cmax [maximum concentration] of 56 [standard devi-
ation 66] ng/mL at 1.5 h after a 100mg dose).33 The CSF AGP range
was higher than the reported reference range of 1.5–4.5 mg/mL.34,35
Based on the CSF concentrations and a Kd of dasatinib for AGP of
2.7 mM,33 70% to 97% of the CSF dasatinib would be unbound. In
plasma, assuming 0.6 mM albumin and the AGP range, 1% to 3%
of dasatinib would be unbound. The CSF/plasma dasatinib ratio of
median 0.66% (range, 0.1% to 16%) therefore suggests that
unbound plasma dasatinib concentrations are the main driving force
for CSF concentrations. Dasatinib CSF concentrations were reported
previously, but detectable concentrations of dasatinib were seen in
only 6 patients. Only 3 patients had CSF/plasma ratios determined
(reported as 5%, 8%, and 28%). The authors concluded that dasati-
nib CNS penetration was considerably higher than that of imatinib
(brain penetrance, 0.5% to 2%).36 Our large dataset from 39 patients
without active CNS leukemia revealed that dasatinib CSF penetration
is largely dependent on free plasma concentrations and is similar to
imatinib.
Our results confirm the high efficacy and safety of induction with dasa-
tinib and dexamethasone for Ph-positive ALL. RIC allogeneic HCT
was feasible and effective after dasatinib-based therapy, and mainte-
nance dasatinib waswell tolerated after allogeneic HCT. As such, allo-
geneic HCT remains a standard of care for Ph-positive ALL and may
be superior option after low-intensity induction. T315I mutation was
the major cause of treatment failure and may be overcome by ponati-
nib or other targeted therapies such as blinatumomab in the future,
potentially obviating the need for allogeneic HCT.
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